Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Sun Pharma and Moebius Medical announce dual publications on MM-II’s phase 2b clinical trial results in Osteoarthritis and Cartilage

Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles

AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

Shin-Etsu Chemical and Hokkaido University develop lipid nanoparticle production system capable of both small-batch, high-mix production

Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US

Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities

Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms

Findings likely to generate hypotheses about potential new uses of drugs

Mankind unveils HealthOK’s 100% vegetarian multivitamin tablets campaign with Archana Puran Singh

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care